MedTrace Logo

Keyhole Limpet Hemocyanin in Chronic Hepatitis C

NCT01509391 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2012-10-17

No results posted yet for this study

Summary

In this study the investigators examine the safety and efficacy of Keyhole-limpet-hemocyanin in patients with chronic hepatitis c infection and liver cirrhosis. The investigators hypothesize that administration of keyhole-limpet-hemocyanin reduces the viral load in patients infected with hepatitis c.

Conditions

Interventions

DRUG

keyhole-limpet hemocyanin

Subcutaneous administration keyhole-limpet hemocyanin

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Rudolf E Stauber, MD · Medical University of Graz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01509391 on ClinicalTrials.gov